PMID: 3765552Jan 1, 1986Paper

Therapy in cytopenia

Vox Sanguinis
J Bussell

Abstract

Intravenous immunoglobulin (IVIG) may be considered first-line maintenance therapy for idiopathic thrombocytopenic purpura (ITP) because it has been proven to be the least toxic. In a study of 25 children with acute ITP, treatment with IVIG maintained platelet counts above 40,000/mm3 in all of the children. After 1 year, none of these patients required further therapy. In another study group of 25 pediatric patients with chronic ITP, treatment with IVIG circumvented splenectomy in 60% of the cases. The therapeutic regimens for adults and children are described, as is a strategy to overcome IVIG resistance. Experience with IVIG in hemolytic anemia and neutropenia are discussed. The mechanism of action is explored in some detail, specifically as it relates to reticuloendothelial system (RES) Fc receptor blockade and suppression of antiplatelet antibody synthesis.

Citations

Aug 14, 2001·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·S M Henry
Aug 1, 1994·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·R I Schiff
Apr 1, 1989·Transfusion Medicine Reviews·L K Boshkov, J G Kelton
Sep 15, 2000·Clinics in Perinatology·R D ChristensenL M Rimsza
Oct 15, 1987·Hospital Practice·A B Minnefor, J M Oleske
Sep 15, 1991·Cancer·R A Good, E Lorenz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.